头孢洛扎/他唑巴坦治疗广泛耐药铜绿假单胞菌引起的骨髓炎和皮肤软组织感染：临床和微生物学结局。
Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
机构信息
Infectious Diseases Unit, Internal Medicine Department, Hospital Universitari Mútua Terrassa, Plaza Dr. Robert 5, 08223 Terrassa, Barcelona, Spain.
Infectious Diseases Unit, Internal Medicine Department, Hospital Universitari Mútua Terrassa, Plaza Dr. Robert 5, 08223 Terrassa, Barcelona, Spain.
出版信息
Int J Antimicrob Agents. 2018 Mar;51(3):498-502. doi: 10.1016/j.ijantimicag.2017.11.003. Epub 2017 Nov 20.
Infections due to multidrug-resistant bacteria (MDR) are currently a clinical challenge, mainly in elderly patients. The antimicrobial spectrum, safety and efficacy of ceftolozane/tazobactam (C/T) make it an attractive option for the treatment of MDR bacterial infections beyond the indications approved to date. Here we report our experience with C/T in four cases of osteomyelitis and three cases of skin and soft-tissue infections due to extensively-drug-resistant Pseudomonas aeruginosa.
目前，多重耐药菌（MDR）感染是临床面临的一项挑战，主要发生于老年患者。头孢他洛滨/他唑巴坦（C/T）的抗菌谱广、安全性好、疗效确切，为治疗多重耐药菌感染提供了一种有吸引力的选择，超出了目前已批准的适应证。在此，我们报告了 C/T 治疗 4 例骨髓炎和 3 例广泛耐药铜绿假单胞菌引起的皮肤和软组织感染的经验。
Zotero 插件